<DOC>
	<DOCNO>NCT00134303</DOCNO>
	<brief_summary>This comparison metformin versus placebo NASH patient receive bariatric surgery obesity .</brief_summary>
	<brief_title>Trial Comparing Metformin Versus Placebo Non Alcoholic Steatohepatitis ( NASH ) Patients Receiving Bariatric Surgery Obesity</brief_title>
	<detailed_description>In patient receive bariatric surgery , preoperative liver biopsy confirm presence NASH . Those patient NASH ( histologically define accord Brunt 's criterion ) randomize receive metformin ( 2 time 850 mg orally daily ) placebo time period 1 year . A control liver biopsy perform one year .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients receive bariatric surgery obesity Other cause liver disease ( hepatitis B virus [ HBV ] , hepatitis C virus [ HCV ] , primary biliary cirrhosis [ PBC ] , etc . ) Patients diabetes type I Patients endocrinological reason obesity ( eg . Cushing , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>